Vilon vs Exenatide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Half-Life
- Very short as a free dipeptide; effects mediated via gene regulation
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 1–2 mg SC daily or 5–10 mg oral daily
- 5 mcg, titrate to 10 mcg
- Frequency
- Once daily
- Twice daily
- Key Benefits
- Immune system modulation and restoration
- Lifespan extension (30–40% in animal studies)
- T-cell and NK-cell activation
- Epigenetic anti-aging activity
- Reduces oxidative stress markers
- Antioxidant gene upregulation
- May prevent age-related immune senescence
- Anti-tumor immune surveillance
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Side Effects
- Excellent safety profile, decades of Russian clinical use
- Rare: mild injection site reaction
- Very rare: mild allergic reaction
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Stacks With
- —
- —